Orlei R. De Araújo

Orlei R. De Araújo

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
GSGlaucia T. F. Seixas
Glaucia T. F. Seixas
OAOrlei R. De Araújo
Orlei R. De Araújo
DSDafne C. B. Silva
Dafne C. B. Silva
RARodrigo G. Arduini
Rodrigo G. Arduini
APAntonio S. Petrilli
Antonio S. Petrilli
To obtain pharmacokinetic and pharmacodynamic data for vancomycin in a cohort of critically ill pediatric oncology patients, we analyzed 256 measurements of vancomycin concentrations in 94 patients. Variables were tested as possible risk factors for vancomycin-related nephrotoxicity or death for 28 days. We found the following: mean vancomycin trough serum concentration, 15.6 ± 12.4 μg/mL; mean vancomycin clearance, 0.16 ± 0.098 L/h/kg; and mean vancomycin distribution volume, 1.04 ± 0.11 L/kg. Only 13.6% of serum trough level measurements were between 15 and 20 μg/mL. The trough levels showed a strong correlation with the AUC (area under the curve of serum concentrations vs. time over 24 h to the minimum inhibitory concentration ratio), with a 94% positive predictive value for AUC/MIC ≥ 400, but only for MIC=1. The doses that are currently used (60 mg/kg/d) attained the therapeutic target (AUC/MIC ≥ 400) in only 56% of measurements, considering MIC=1. A serum trough level of ≥ 20 μg/mL was an independent risk for nephrotoxicity (P = 0.0008; odds ratio = 17.83). Vancomycin-related nephrotoxicity was a predictor of death for up to 28 days (P = 0.003, odds ratio = 7.68). Currently administered doses of vancomycin do not reach the therapeutic target for critical cancer patients, particularly if staphylococci isolates have a MIC>1.

1 July 2012 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
DSDáfne Cardoso Bourguignon da Silva
Dáfne Cardoso Bourguignon da Silva
GSGláucia Toribio Finoti Seixas
Gláucia Toribio Finoti Seixas
OAOrlei R. De Araújo
Orlei R. De Araújo
RARodrigo Genaro Arduini
Rodrigo Genaro Arduini
FCFabianne Altruda de Moraes Costa Carlesse
Fabianne Altruda de Moraes Costa Carlesse
APAntonio Sergio Petrilli
Antonio Sergio Petrilli
Usual treatment regimens with vancomycin often fail to provide adequate serum levels in patients with severe infections. Retrospective analysis of vancomycin trough serum measurements. The following parameters were calculated by Bayesian analysis: vancomycin clearance, distribution volume, and peak estimated concentrations. The area under the concentration curve (AUC) (total daily dose/24 h clearance of vancomycin) was used to determine the effectiveness of treatment through the ratio of AUC/minimum inhibitory concentration (MIC) above 400, using MIC=1 μg/mL, based on isolates of Staphylococci in cultures. Sixty-one vancomycin trough measurements were analyzed in 31 patients. AUC/MIC>400 was obtained in 34 out of 61 dosages (55.7%), but the mean vancomycin dose required to achieve these levels was 81 mg/kg/day. In cases where the usual doses were administered (40-60 mg/kg/day), AUC/MIC>400 was obtained in nine out of 18 dosages (50%), in 13 patients. Trough serum concentrations above 15 mg/L presented a positive predictive value of 100% and a negative predictive value of 71% for AUC/MIC>400. Higher than usual vancomycin doses may be required to treat staphylococcal infections in children with oncologic/hematologic diseases. Since the best known predictor of efficacy is the AUC/MIC ratio, serum trough concentrations must be analyzed in conjunction with MICs of prevalent Staphylococci and pharmacokinetic tools such as Bayesian analysis.

19 February 2013 in BMJ Open
Verified
Journal Article
Open access
PDF file
DSDafne C B Silva
Dafne C B Silva
OAOrlei R. De Araújo
Orlei R. De Araújo
RARodrigo G Arduini
Rodrigo G Arduini
CACarolina F R Alonso
Carolina F R Alonso
ASAudrey R O Shibata
Audrey R O Shibata
ETEduardo J Troster
Eduardo J Troster
Objectives To describe adverse drug events (ADEs) in children under intensive care, identify risk factors and tools that can detect ADEs early, and the impact on length of stay (LOS). Design A prospective observational study. Setting Paediatric intensive care unit of a tertiary care teaching hospital. Patients 239 patients with a mean age of 67.5 months representing 1818 days of hospitalisation in intensive care unit. Interventions Active search of charts and electronic patient records using triggers. The statistical analysis involved linear and logistic regression. Measurements and main results The average LOS was 7.6 days. There were 110 proven, probable and possible ADEs in 84 patients (35.1%). We observed 138 instances of triggers. The major classes of drugs associated with events were: antibiotics (n=41), diuretics (n=24), antiseizures (n=23), sedatives and analgesics (n=17) and steroids (n=18). The number of drugs administered was most related to the occurrence of ADEs and also to the LOS (p<0.001). The occurrence of an ADE may result in an increase in the LOS by 1.5 days per event, but this was not statistically significant in this sample. Patients aged less than 48 months also proved to be at a significant risk for ADEs, with an OR of 1.84 (95% CI 1.07 to 3.15, p=0.025). The number of drugs administered also correlated with the number of ADEs (p<0.0001). The chance of having at least one ADE increased linearly as the patient was administered more drugs. Conclusions The use of multiple drugs as well as lower patient age favours the occurrence of ADEs. The active search described here provides a systematic approach to this problem.

10 September 2021 in Jornal de Pediatria
Verified
Journal Article
Open access
OAOrlei R. De Araújo
Orlei R. De Araújo
RARafael Teixeira Azevedo
Rafael Teixeira Azevedo
FOFelipe Rezende Caino de Oliveira
Felipe Rezende Caino de Oliveira
JJJosé Colleti Junior
José Colleti Junior
To evaluate current practices of tracheostomy in children regarding the ideal timing of tracheostomy placement, complications, indications, mortality, and success in decannulation. The authors searched PubMed, Embase, Cochrane Library, Google Scholar, and complemented by manual search. The guidelines of PRISMA and MOOSE were applied. The quality of the included studies was evaluated with the Newcastle-Ottawa Scale. Information extracted included patients’ characteristics, outcomes, time to tracheostomy, and associated complications. Odds ratios (ORs) with 95% CIs were computed using the Mantel-Haenszel method. Sixty-six articles were included in the qualitative analysis, and 8 were included in the meta-analysis about timing for tracheostomy placement. The risk ratio for “death in hospital outcome” did not show any benefit from performing a tracheostomy before or after 14 days of mechanical ventilation (p = 0.49). The early tracheostomy before 14 days had a great impact on the days of mechanical ventilation (-26 days in mean difference, p < 0.00001). The authors also found a great reduction in hospital length of stay (-31.4 days, p < 0.008). For the days in PICU, the mean reduction was of 14.7 days (p < 0.007). The meta-analysis suggests that tracheostomy performed in the first 14 days of ventilation can reduce the time spent on the ventilator, and the length of stay in the hospital, with no effect on mortality. The decision to perform a tracheostomy early or late may be more dependent on the baseline disease than on the time spent on ventilation .

15 January 2020 in Jornal de Pediatria
Verified
Journal Article
Open access
JJJosé Colleti Junior
José Colleti Junior
RARafael de Azevedo
Rafael de Azevedo
OAOrlei R. De Araújo
Orlei R. De Araújo
WCWerther Brunow de Carvalho
Werther Brunow de Carvalho
Perform a systematic review and meta-analysis to assess the effectiveness and complications caused by the use of the high-flow nasal cannula in relation to the post-extubation continuous positive airway pressure system in preterm newborns. The searches were performed from January 2013 to December 2018 in the PubMed and Embase databases, as well as a manual search on the internet. Two reviewers independently conducted the search, and a third reviewer resolved questions that arose. Ninety-eight articles from the chosen sources were evaluated, and 66 were discarded because they did not meet the inclusion criteria (inadequate topic, age range, or design, in addition to the duplicates). Fifteen articles were read in full, and five more were discarded due to inadequacy to the topic or design. There were ten articles left for systematic review and four for meta-analysis. The study showed non-inferiority in terms of therapeutic failure of the high-flow nasal cannula in relation to continuous positive airway pressure after extubation of preterm newborns. In the meta-analysis, nasal trauma was significantly lower in patients submitted to the high-flow nasal cannula compared to those using continuous positive airway pressure (p<0.00001). The high-flow nasal cannula is not inferior to continuous positive airway pressure for post-extubation respiratory support in preterm newborns with a gestational age of 32 weeks or less and greater than 28 weeks, in addition to resulting in less nasal trauma.

1 April 2007 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
OAOrlei R. De Araújo
Orlei R. De Araújo
DSDafne Cardoso Bourguignon da Silva
Dafne Cardoso Bourguignon da Silva
ADAna Regina Diegues
Ana Regina Diegues
RARonaldo Arkader
Ronaldo Arkader
ECEloíza Aparecida Ferreira Cabral
Eloíza Aparecida Ferreira Cabral
AAAndréa de Cássia Stéfano Albertoni
Andréa de Cássia Stéfano Albertoni
Antibiotic restriction can be useful in maintaining bacterial susceptibility. The objective of this study was verify if restriction of cefepime, the most frequently used cephalosporin in our neonatal intensive care unit (NICU), would ameliorate broad-spectrum susceptibility of Gram-negative isolates. Nine hundred and ninety-five premature and term newborns were divided into 3 cohorts, according to the prevalence of cefepime use in the unit: Group 1 (n=396) comprised patients admitted from January 2002 to December 2003, period in which cefepime was the most used broad-spectrum antibiotic. Patients in Group 2 (n=349) were admitted when piperacillin/tazobactam replaced cefepime (January to December 2004) and in Group 3 (n=250) when cefepime was reintroduced (January to September 2005). Meropenem was the alternative third-line antibiotic for all groups. Multiresistance was defined as resistance to 2 or more unrelated antibiotics, including necessarily a third or fourth generation cephalosporin, piperacillin/tazobactam or meropenem. Statistics involved Kruskal-Wallis, Mann-Whitney and logrank tests, Kaplan-Meier analysis. Groups were comparable in length of stay, time of mechanical ventilation, gestational age and birth weight. Ninety-eight Gram-negative isolates were analyzed. Patients were more likely to remain free of multiresistant isolates by Kaplan-Meier analysis in Group 2 when compared to Group 1 (p=0.017) and Group 3 (p=0.003). There was also a significant difference in meropenem resistance rates. Cefepime has a greater propensity to select multiresistant Gram-negative pathogens than piperacillin/tazobactam and should not be used extensively in neonatal intensive care.